Welcome to the OMA Blog

Metabolic associated liver disease (MASLD) is the most common chronic liver disease globally, linked to obesity and insulin resistance, with a growing prevalence in children. Early life factors such as maternal BMI, gestational diabetes, and breastfeeding play crucial roles in influencing the risk and progression of MASLD, highlighting the need for further research and preventive measures.

Highlighting Advocacy: Providing care to patients with obesity can be complex. The Obesity and Advocacy joint statement from the Obesity Medicine Association and the Obesity Action Coalition 2024 provides a clinical focus, an action-based framework, and a guide for health care providers.

Understand the link between inflammation, obesity, and how the Dietary Inflammatory Index can help mitigate health risks associated with chronic inflammation.

The Obesity Medicine Association (OMA) is the oldest and largest organization of clinicians in the obesity treatment space. In 2024, it partnered with Project ECHO to create the program entitled, Treating the Disease of Obesity. Ethos of this program includes (1) obesity is a chronic and relapsing disease and (2) the use of person-first language (eg. “the patient with obesity” instead of “the obese patient”). The first session was in February 2024 by Dr. Angela Fitch, the Past President of OMA. She presented the four core pillars of clinical obesity treatment. Content from this presentation is described in this blog article.

Discover how weight loss medications affect pregnancy and fertility with the latest insights, research, and safety recommendations for patients.

In an effort to combat obesity, the Mississippi Obesity Society stands as a strong example of the dedication and compassion that is needed to address a disease like obesity. Founded just a year ago, this dynamic organization is dedicated to improving the lives of Mississippians by enhancing health awareness and access to resources.

Research has shown that obesity is reported to be a public crisis in the US (1,2,3). Worldwide obesity has tripled since 1975 (18). Obesity is…

Our society can be hostile toward people with obesity who commonly face judgment, prejudice, and unfair treatment in their daily lives. This problem extends to the healthcare setting, where patients can face weight bias and stigma from physicians, nurses, psychologists, dietitians, medical students, and even healthcare professionals who specialize in obesity.

Insulin is a commonly used medication to treat patients with both type 1 and type 2 diabetes. Weight gain is a commonly seen side effect. Patients may have questions about insulin and potential weight gain out of concern for their appearance or their health (or both).